# EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study

> **NCT00216255** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Persistent Developmental Stuttering

## Interventions

- **DRUG:** Pagoclone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00216255
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216255, "EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00216255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*